Natixis Purchases 13,532 Shares of Eli Lilly and Company $LLY

Natixis increased its position in shares of Eli Lilly and Company (NYSE:LLY) by 5.9% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 242,053 shares of the company’s stock after acquiring an additional 13,532 shares during the period. Eli Lilly and Company comprises 0.8% of Natixis’ holdings, making the stock its 16th largest holding. Natixis’ holdings in Eli Lilly and Company were worth $188,688,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Brighton Jones LLC grew its position in Eli Lilly and Company by 22.0% in the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock valued at $7,409,000 after acquiring an additional 1,730 shares during the last quarter. Revolve Wealth Partners LLC increased its position in Eli Lilly and Company by 2.8% during the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock worth $1,136,000 after purchasing an additional 40 shares in the last quarter. Kaufman Rossin Wealth LLC bought a new position in Eli Lilly and Company in the 1st quarter valued at approximately $242,000. Connor Clark & Lunn Investment Management Ltd. boosted its position in Eli Lilly and Company by 16.0% in the first quarter. Connor Clark & Lunn Investment Management Ltd. now owns 34,018 shares of the company’s stock valued at $28,096,000 after buying an additional 4,688 shares in the last quarter. Finally, Koss Olinger Consulting LLC bought a new stake in shares of Eli Lilly and Company during the first quarter worth $388,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock opened at $1,009.26 on Monday. The business has a 50-day moving average price of $918.84 and a two-hundred day moving average price of $810.35. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,111.99. The company has a current ratio of 1.55, a quick ratio of 1.24 and a debt-to-equity ratio of 1.71. The company has a market cap of $954.13 billion, a P/E ratio of 49.38, a PEG ratio of 1.12 and a beta of 0.37.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, October 30th. The company reported $7.02 EPS for the quarter, beating the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The company had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. During the same quarter in the prior year, the company earned $1.18 EPS. The firm’s revenue for the quarter was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th will be issued a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 29.35%.

Analyst Upgrades and Downgrades

LLY has been the topic of several recent research reports. Truist Financial raised their price objective on Eli Lilly and Company from $1,038.00 to $1,182.00 and gave the company a “buy” rating in a report on Wednesday, November 19th. Wall Street Zen upgraded shares of Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 1st. Guggenheim restated a “buy” rating and issued a $1,163.00 price target on shares of Eli Lilly and Company in a research report on Wednesday. Loop Capital set a $950.00 price target on shares of Eli Lilly and Company in a report on Monday, November 10th. Finally, Hsbc Global Res raised Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a research report on Wednesday, August 27th. Three research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,087.32.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.